319 results
8-K
EX-1.1
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
responsibility for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make an appraisal … deliverables included in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company with responsibility for financial
8-K
EX-99.2
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness
8-K
EX-10.1
8jqszek ha956yei
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
8-K
EX-99.1
20e24ny4qk00 l5
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
424B5
0o1yfc7o
16 Feb 24
Prospectus supplement for primary offering
6:01am
8-K
EX-99.1
hvzrvgd po
24 Jan 24
Regulation FD Disclosure
2:12pm
S-8
EX-4.1
mwoq695rzvsnybpye
18 Jan 24
Registration of securities for employees
2:38pm
8-K
EX-99.1
ehgwx
4 Jan 24
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide
5:07pm
8-K
EX-99
z97z6zcz7ig3xz4xe87
16 Oct 23
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
1:13pm
8-K
EX-99.1
p9m6yx8 gpxpk8y
12 Oct 23
Lexaria Granted Two New Patents in Canada
3:57pm
8-K
EX-1.1
q5h0ny8w mz4iu0tqyg
3 Oct 23
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.1
2w5ct
3 Oct 23
Entry into a Material Definitive Agreement
4:05pm
424B5
lw3hc91 tgxxu4
2 Oct 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
r93mapkt8r5jrtei
28 Jul 23
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
12:11pm
8-K
EX-99.1
nkeui7j gratf888edq
10 May 23
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
5:16pm